Thank you to all our Partner organisations:
Astrazeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas- Oncology, Cardiovascular, Renal & Metabolism and Respiratory. For more information, please visit www.astrazeneca.co.uk.
Boehringer Ingelheim has 100 years of heritage in respiratory disease.
Since 1921 we have emerged as a leader in this disease area, having developed and launched treatments for a range of respiratory conditions including lung cancer, asthma, chronic obstructive pulmonary disease (COPD), treatment of adults with idiopathic pulmonary fibrosis (IPF) and other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
Our continued focus is on improving the life of patients suffering from debilitating respiratory diseases.
PC-GB-105963 Date of preparation; November 2021
Boehringer Ingelheim (BI) has provided financial support to ARNS as a partnership for 2023. The funding enabled ARNS to provide ongoing education and development for respiratory nurses. BI has had no input into ARNS activities other than an exhibition stand and a symposium slot at the annual conference.
Based in Parma, Italy, Chiesi Farmaceutici is an international research-focused biopharmaceuticals group with over 85 years’ experience in the pharmaceutical sector operating in 30 countries, employing around 6,000 people. Chiesi develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. Chiesi Limited is headquartered in Manchester employing over 400 people.
Further information: www.chiesi.uk.com
Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. We are powered by purpose, a purpose to serve patients and their families with unwavering dedication. A purpose to find solutions where there were none before. A purpose to do what’s right, even when it isn’t easy. A biotech company that empowers great people to deliver, with a profound sense of urgency and compassion, life-altering therapies to small patient populations experiencing big health problems.
A global leader in interventional pulmonology, planning tools, and treatments for obstructive lung disease.
Based in Redwood City, California, and Neuchâtel, Switzerland, Pulmonx is the maker of the Zephyr Endobronchial Valve. The Zephyr® Valve was granted breakthrough status and approved by the FDA in June 2018, because according to the FDA it “represents a breakthrough technology as the device offers bronchoscopic lung volume reduction without surgery and its associated risks. This device offers a significant, clinically meaningful advantage over the current standard of care and therefore, its availability is also in the best interest of patients.”
The company’s commercially available portfolio includes the Zephyr Endobronchial Valve. More than 100 scientific articles have been published on the clinical benefits of Zephyr Valves, including multiple meta-analyses, review articles, cost-effectiveness analyses and risk-benefit analyses.